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Vietnam is ranked 13th among the WHO list of 22 high-burden countries, based upon estimated total
number of tuberculosis cases. Despite having a model national tuberculosis program, consistently achieving
and exceeding WHO targets for detection and cure, drug-resistant and multidrug-resistant tuberculosis cases
continue to rise. Rapid multidrug-resistant tests applicable in this setting, coupled with effective treatment
regimens, would be a useful tool in reversing this trend, allowing early identification of patients with multidrug-
resistant tuberculosis and avoiding resistance-amplifying regimens. Sequencing of consecutive isolates iden-
tified by the National Tuberculosis Program showed 89% of isoniazid-resistant isolates could be detected by
targeting just 2 codons, katG 315 and 15C3T in the inhA promoter, while rifampin resistance will be more
complex to detect, with many different mutation and insertion events in rpoB. The most prevalent rifampin
resistance-conferring mutations, as in other countries, were in rpoB codons 531 (43%), 526 (31%), and 516
(15%). However, a hybridization-based resistance test with probes targeting the 5 most common mutations
would only detect 78% of rifampin-resistant isolates. Overall, these data suggest that rifampin resistance may
be used as a surrogate marker for multidrug-resistant tuberculosis and that a sensitivity of between 70 to 80%
may be possible for rapid molecular detection of multidrug-resistant tuberculosis in this setting.
Few data are available on resistance among Mycobacterium
tuberculosis isolates in Vietnam. The latest figures from the
WHO are derived from the 1997 report on global drug resis-
tance, which estimates resistance to any drug from a 1996
survey at 32.5% and multidrug-resistant (MDR) tuberculosis
(TB) at 2.3% (35). The second national drug resistance survey
was carried out between 2001 and 2002, but there were prob-
lems with data collection. The third survey is under way.
There are indications that the incidence of MDR TB has
risen significantly since the first survey and, in the face of a
rapidly increasing human immunodeficiency virus prevalence
in Vietnam, is likely to continue to increase in the coming
years. The International Organization for Migration (IOM)
reported from a study of potential immigrants to Canada be-
tween 1989 and 2000 that the estimated MDR TB rate was
approximately 4.5% (32), and data from our own studies show
the rate of MDR TB in 2002 to 2004 to be approximately 6%
(unpublished data).
The National Tuberculosis Program (NTP), while appar-
ently achieving high rates of detection and cure (12), is not able
to offer sensitivity testing on all isolates. Patients currently
receive a standard regimen upon diagnosis of 2 months of
streptomycin (S), isoniazid (H), rifampin (R), and pyrazin-
amide (Z), followed by 6 months of isoniazid and ethambutol
(E) (2SHRZ/6HE). Following microbiological failure or re-
lapse, there is a retreatment regimen of 2 months of strep-
tomycin, isoniazid, rifampin, pyrazinamide, and ethambutol,
followed by 1 month of isoniazid, rifampin, pyrazinamide,
and ethambutol, and finally, 5 months of isoniazid, rifampin,
and ethambutol (2SHRZE/1HRZE/5H3R3E3). A 2003 study
showed that 47% of patients who failed treatment within the
NTP had primary MDR TB (24), and in a separate study, only
33% of MDR TB patients were sputum smear negative upon
completion of 8 months of retreatment (17).
Effective control and treatment of MDR TB will require
earlier diagnosis and a change in treatment patterns to avoid
potential resistance-amplifying regimens (7).
Studies have shown that the mutations responsible for drug
resistance in M. tuberculosis vary geographically (22). It is not
clear if this is secondary to prescribing practices, M. tubercu-
losis strain subtypes, or other factors.
The development of a sensitive, rapid, and economical ge-
notypic test for MDR TB will require knowledge of the prev-
alent mutations among MDR TB isolates in Vietnam. This
study aimed to characterize the mutations conferring resis-
tance in 100 consecutive rifampin (RIF)-resistant isolates and
100 consecutive isoniazid (INH)-resistant isolates identified at
Pham Ngoc Thach Hospital, the WHO coordinating center for
the NTP in southern Vietnam.
MATERIALS AND METHODS
Pham Ngoc Thach Hospital is a 500-bed hospital for tuberculosis and lung disease
serving Ho Chi Minh City and is a tertiary referral hospital for southern Vietnam.
The microbiology laboratory is a WHO international reference laboratory. Between
January and March 2005, consecutive M. tuberculosis isolates identified at Pham
Ngoc Thach Hospital and shown to be resistant to either RIF or INH had their
relevant genes sequenced at the Hospital for Tropical Diseases, Ho Chi Minh City.
Isolates are tested in the NTP following failure of directly observed therapy-short
course (DOTS) or at the request of the treating physician.
Susceptibility testing was routinely performed by the standard 1% proportion
method on Lowenstein-Jensen media for INH (0.2 g/ml), RIF (40 g/ml),
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streptomycin (4 g/ml), and ethambutol (2 g/ml). All isolates were identified as
M. tuberculosis by standard phenotypic identification tests. Data on the residen-
tial district were collected to ensure that isolates were not part of a single
outbreak or from one residential district of the city (data not shown).
PCR and DNA sequencing. For isolates resistant to rifampin, the rpoB ri-
fampin resistance-determining region (RRDR, codons 409 to 493) was se-
quenced. If no mutations were found, further sequencing was done at the rpoB
N-terminal (codons 111 to 200) and cluster 3 (codons 575 to 656) regions. For
isoniazid-resistant isolates, a 381-bp (codons 266 to 392) region of katG was
sequenced. If no mutations were seen in katG, two further regions involved in
INH resistance were sequenced: the oxyR-ahpC intergenic region (codons oxyR
56 to ahpC 97) and inhA promoter region (codons 93 to 27). Primers (Proligo,
Singapore) are given in Table 1.
PCRs for rpoB N-terminal, cluster III, oxyR-ahpC intergenic, and inhA pro-
moter regions were performed with 0.75 U of Bioline Taq (Bioline, United
Kingdom) polymerase, RRDR PCR used 0.75 U of Amersham Taq polymerase
(Amersham, United Kingdom), and katG whole-gene PCR used 1.3 U of the
Expand high-fidelity polymerase system (Roche, United Kingdom). Amplifica-
tions were carried out in an Eppendorf Mastercycler as follows: an initial step of
95°C for 3 min, 30 cycles of 95°C for 15 s, appropriate annealing temperature
(Ta) for 15 s, 72°C for 15 s, and a final step of 72°C for 2 min. katG whole-gene
PCR used 2.5 min at 72°C for extension and a final step of 72°C for 7 min.
PCR products were purified with QIAgen PCR purification kits (QIAGEN,
United Kingdom) and then served as templates for cycle sequencing reactions.
Both strands of each product were sequenced with CEQ dye terminator cycle
sequencing quick start kits (Beckman Coulter, Singapore) in a half-volume
reaction using PCR primers, except for katG, which was sequenced with katGP5
and katGP6 (21). The thermal cycling program was 96°C for 20 s, appropriate Ta
for 20 s, and 60°C for 4 min for 30 cycles, followed by holding at 4°C. The cycle
sequencing products were subjected to ethanol precipitation steps according to
the manufacturer’s instructions and sequenced on the CEQ8000 system (Beck-
man Coulter, Singapore).
RESULTS
One hundred thirty-one consecutive isolates resistant to ei-
ther RIF or INH were collected. Resistance patterns to first-
line drugs are shown in Table 2. One hundred four isolates
(79%) were RIF resistant; 129 isolates (98%) were INH resis-
tant. Only 2 (1.9%) RIF-resistant isolates were not MDR: one
of these was RIF monoresistant and the other was resistant to
RIF and streptomycin.
One hundred four RIF-resistant isolates had the rpoB
RRDR sequenced. The most prevalent mutations were at
codons 531 (43%), 526 (31%), and 516 (15%). In total, muta-
tions were found in 11 different codons, 10 isolates had muta-
tions at multiple codons, and two insertions in codons 514 and
521 were also identified. Mutations identified in rpoB in 104
rifampin-resistant isolates are shown in Table 3.
Five isolates showing no RRDR mutations had their N-
terminal regions sequenced. One previously reported muta-
tion, V146F, was found in the N-terminal region, and three
isolates carried a mutation at codon 561, just outside cluster 2.
These five isolates also had the cluster 3 region sequenced, but
no further mutations were identified.
The first 100 isolates resistant to INH had katG sequenced.
The majority of isolates, 71%, carried the G944C (S315T)
mutation, while two isolates carried G944A (S315N) muta-
tions, two carried G944T (S315I) mutations, and one carried a
A943G (S315G) mutation. Two isolates carried double muta-
tions: one G944C/C924T (S315T/T308T) and one a dual mu-
tation in codon 315, G944C/C945G (S315T). One isolate ap-
peared to have a deleted katG gene.
Twenty-one isolates with wild-type katG had their inhA and
oxyR-ahpC region sequences determined. Ten isolates carried
a 15C3T mutation in the inhA promoter, 1 isolate had a
silent mutation in ahpC (C21A), 11 isolates carried a silent
mutation in the oxyR pseudogene (G37A), and 6 isolates carried
different mutations in the oxyR-ahpC intergenic region (81C-T,
51G-A, 48G-A, 74G-A, 72C-T, and 51G-A).
TABLE 1. Primers for sequencing of rifampin and isoniazid resistance-determining regions
Primer
(reference) Sequence (5–3) Ta (°C) Concn (nM) Target
Product length
(bp)
katGwgF1 GTC CTC TAT ACC GGA CTA CGC 61 120 katG whole gene 2,899
katGwgR1 TCG CAC ATC CAG CAC ATT TC
katGP5 GGT CGA CAT TCG CGA GAC GTT 68 katG codon 315, sequencing primers 518
katGP6 (21) CGG TGG ATC AGC TTG TAC CAG
TB92 CCT CGC TGC CCA GAA AGG GA 56 150 inhA promoter region 248
TB93 (29) ATC CCC CGG TTT CCT CCG GT
AhpC1 GCC TGG GTG TTC GTC ACT GGT 56 150 oxyR-ahpC intergenic region 359
AhpC2 (28) CGC AAC GTC GAC TGG CTC ATA
RPOBF GGG AGC GGA TGA CCA CCC A 65 125 rpoB RRDR 350
RPOBR (14) GCG GTA CGG CGT TTC GAT GAA C
TB146-F CTT CTC CGG GTC GAT GTC GTT G 64 300 rpoB N-terminal region 365
TB146-R (8) CGC GCT TGT CGA CGT CAA ACT C
RpoB-C3F GAG TAC GTG CCC TCG TCT GA 56 300 rpoB cluster 3 region 319
RpoB-C3R ACT TGC GCA TCC GGT AGG TA
TABLE 2. Resistance patterns in 131 consecutive isolates resistant to
either isoniazid or rifampin identified at Pham Ngoc Thach Hospital
for Tuberculosis and Lung Diseases in southern Vietnam
Resistance
patterna
No. (%)
of isolates
H ................................................................................................ 5 (3.8)
R................................................................................................. 1 (0.8)
HE.............................................................................................. 2 (1.5)
HR ............................................................................................. 4 (3.0)
HS .............................................................................................. 19 (14.5)
RS .............................................................................................. 1 (0.8)
HRE........................................................................................... 3 (2.3)
HRS ........................................................................................... 58 (44.3)
HSE ........................................................................................... 1 (0.8)
HRSE ........................................................................................ 37 (28.2)
Total...........................................................................................131 (100)
a H, isoniazid; R, rifampin; S, streptomycin; E, ethambutol.
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DISCUSSION
These data indicate that rifampin resistance would be a good
surrogate marker for MDR TB in this setting, with 98% of
rifampin-resistant isolates also MDR. However, the molecular
detection of rifampin resistance in Vietnam will be complex,
with many single point mutations scattered in the RRDR,
multiple mutations, and insertion events. The general pattern
of rpoB mutations reflects those found worldwide, with codons
531 (43%), 526 (31%), and 516 (15%) being the most com-
monly mutated. Four isolates (4%) had no mutations in any
region sequenced for rifampin resistance, as has been previ-
ously reported (11, 22). While it is possible that these isolates
are due to laboratory error in the assignment of resistance,
consistent reports from many laboratories suggest that another
mechanism is responsible for resistance in these isolates. Al-
ternatively, these isolates may contain a mixed population of
resistant and susceptible organisms (8).
Two rare insertions were identified, 514F, reported else-
where (10) and 521SGL. The V146F mutation, in the N-
terminal (cluster 2) region, has also been reported else-
where and associated with low-level resistance, though not
exclusively so (9).
Seventy-one percent of INH-resistant isolates carried an
S315T mutation in katG. This mutation has been associated
with high-level (5 g/ml) INH resistance (31) but, again, not
exclusively so (25, 31), with MICs ranging from 0.38 to 12
g/ml. A further 7 (7%) isolates had different mutations in
codon 315. In total, 78% of INH-resistant isolates carried a
mutated KatG codon 315. One of these isolates carried a dou-
ble mutation in codon 315 and one carried a second mutation
at base 924. However, this mutation is synonymous, T308T,
and therefore does not contribute to the resistant phenotype.
Although S315T is the most common mutation worldwide, the
precise functional effect of the mutation remains unclear. The
threonine residue may block access to the active site and re-
duce the INH affinity of the enzyme, or it may alter redox
potentials and local hydrogen bonds (2). The catalase peroxi-
dase remains functional but with reduced activity (26, 33).
One isolate appears to have a deleted katG gene, a rare but
previously reported event. Loss of katG confers high-level
(256 g/ml) INH resistance but probably confers a biological
cost for the bacteria in the form of a decreased ability to fight
oxidative stress (34). Twenty-one isolates carried a wild-type
katG gene. Ten of these (50%) had a15C3T mutation in the
inhA promoter. This mutation generally confers intermediate-
level (0.1 to 0.4 g/ml) resistance (18). Mutations in this pro-
moter region lead to increased inhA expression, overwhelming
the effect of INH at low levels. The INH reactive form, isonic-
otinic acyl radical, reacts with NAD(H) to form a covalent
adduct which blocks the active site of the NADH-dependent
enoyl ACP reductase product of inhA (27).
No mutations were found in ahpC which conferred resis-
tance to INH. One isolate carried a C21A synonymous muta-
tion. Ten isolates also carried the G37A polymorphism in oxyR,
which is nonfunctional in M. tuberculosis, carrying multiple
deletions and mutations (4); therefore, this mutation is un-
likely to confer INH resistance.
Six isolates carried mutations in the oxyR-ahpC intergenic
region, but the significance of this is unclear. Some mutations
in this region, such as C30T, have been shown to upregulate
alkylhydroperoxidase (15), thought to be a compensatory
mechanism for loss of catalase peroxidase activity; other mu-
tations, such as 46G3A (1), have been found in both resis-
tant and susceptible isolates and are not related to INH resis-
TABLE 3. Mutations in the rpoB gene of 104 consecutive rifampin-resistant isolates identified in southern Vietnam
Mutated E. coli codon(s) M. tuberculosis mutation(s) Amino acid change(s) No. (%) of isolates
146 G508T V170F 1 (0.96)
511, 526 T1288C, C1333A L430P, H445N 1 (0.96)
511, 512 T1288C, A1290G L430P, S431G 1 (0.96)
511, 516 T1288C, A1304G L430P, D435G 1 (0.96)
513 C1293A Q432K 2 (1.92)
513 A1294T Q432L 1 (0.96)
513, 526 C1293A, C1333G Q432L, H445D 1 (0.96)
514 Insa: 1299TTC1300 Ins: F, QFM3QFFM 1 (0.96)
516 A1304T D435V 9 (8.65)
516 A1304C D435A 1 (0.96)
516, 526 A1304C, C1333A D435A, H445N 1 (0.96)
516, 526 A1304T, C1335G D435V, H445Q 1 (0.96)
516, 533 A1304G, T1355C D435G, L452P 2 (1.92)
521, 516 Ins: 1320TCGGGGTTG1333, A1304G Ins: SGL, PLSGL3PLSGLSGL, D435G 1 (0.96)
526 C1333T H445Y 14 (13.46)
526 C1333G H445D 6 (5.76)
526 A1334G H445R 5 (4.81)
526 C1333A, A1334G H445S 1 (0.96)
526 C1335G H445Q 1 (0.96)
526 A1334T H445L 1 (0.96)
526 C1333T, A1334T H445F 1 (0.96)
531 C1349T S450L 42 (40.38)
531, 561 C1349T, A1387G S450L, I480V 3 (2.88)
533 T1355C L452P 2 (1.92)
No mutations 4 (3.85)
a Ins, insertion.
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tance but have phylogenetic significance. The functional effect,
if any, of the mutations seen here is not yet known.
Recent reports (5) and theoretical models (6) suggest that
MDR TB can be controlled and reduced through effective
first-line DOTS programs such as the one functioning in Viet-
nam. The reasons for increasing drug resistance, particularly
MDR, despite an effective NTP network remain unclear. How-
ever, both DOTS studies were based on lower underlying levels
of primary drug resistance, and the use of a primary ethambu-
tol-based continuation phase, as in Vietnam, has been shown
to be less effective than rifampin-based regimens and may be a
contributing factor (13). High rates of primary INH (20%) and
streptomycin (31%) resistance and resistance to other first-line
drugs (40% resistant to one or more) may well be a contrib-
uting factor, with many patients effectively receiving ethambu-
tol monotherapy in the continuation phase.
A previous report suggests that 9% of smear-positive TB
patients detected in the Vietnamese NTP in 2000 were not
registered for treatment, suggesting that while detection rates
were high, many of these patients did not progress through
NTP-controlled DOTS (3). Efforts have been made to address
this issue by changes in data management to record all patients
at time of diagnosis, whereas prior to 2000, patients were only
registered at commencement of therapy (12). Private treat-
ment in Vietnam is associated with significantly lower treat-
ment success rates than the NTP (48.9% versus 85%, P 
0.001) (20), probably due to incorrect prescriptions and poor
adherence to therapy for financial and other reasons. It has
been estimated that 40% of all antituberculosis drug dispens-
ing in Vietnam occurs outside the NTP and that a quarter of
these sales are made without a prescription (19).
It is likely that the prevalence figures on which WHO esti-
mates of NTP performance are based (incidence of smear-
positive TB, 85/100,000; prevalence, 96/100,000) (36) are also
low. Wide regional variation in NTP performance, particularly
in rural areas, may be hindering TB control in Vietnam. A
prevalence survey in a rural district of Northwest Vietnam (30)
estimated smear-positive prevalence at 90 to 110/100,000, but
detection in the NTP is only 39% for females and 12% for
males, significantly below the national detection rates. Efforts
are being made by the government to improve NTP perfor-
mance in rural areas.
Screening of applicants for Australian visas in Ho Chi Minh
City by the IOM estimates rates of 157/100,000 for new smear-
positive TB and 489/100,000 of new bacteriologically con-
firmed (smear and culture) TB, a rate 2.5 times that estimated
by the WHO (23). The true incidence rates are unknown. TB
notification rates vary widely across Vietnam, and it is also
possible that the incentive system in the NTP leads to an
overestimation of the cure rate (12). More accurate tubercu-
losis incidence and drug resistance prevalence data will be
useful in addressing MDR TB in Vietnam.
It is likely that the sensitivity of hybridization tests for RIF
resistance will be low in this setting. The commercial INNO-
LiPA Rif.TB test (Innogenetics, Belgium) will directly detect
only 73% through the resistant probes, though sensitivity may
be higher when prediction of resistance through nonhybridiza-
tion to probes for wild-type sequence is included. Probes di-
rected to the 5 most prevalent mutations would achieve a
sensitivity of only 78%. Molecular INH resistance detection
may be simpler, though still incomplete, with combined detec-
tion of mutated codon 315 and 15C3T mutation in the inhA
promoter, allowing a sensitivity of up to 89%. Early detection
of INH resistance may be particularly important in Vietnam,
with high underlying INH resistance (20%) (16; also unpub-
lished data) in conjunction with the use of an ethambutol-
based continuation phase possibly fuelling the development of
MDR TB. Ideally, such a test should be cheap, rapid, and
applicable in low-technology environments to have an impact
in Vietnam.
However, while the molecular detection of neither RIF nor
INH resistance is 100% accurate and the importance of phe-
notypic tests for the exclusion of drug resistance remains, the
earlier detection of resistant cases, particularly MDR TB, will
be an important tool in controlling MDR TB and achieving the
millennium development goals for reductions in TB mortality.
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